RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PETRILLO A
Collezione AOU Città della Salute di Torino

Items : 6

Viral Infection and Antiviral Treatments in Ocular Pathologies. in Microorganisms / Microorganisms. 2022 Nov 10;10(11):2224. doi: 10.3390/microorganisms10112224.

2022
AOU Città della Salute di Torino

Petrillo F; Petrillo A; Sasso FP; Schettino A; Maione A; Galdiero M;

Structured reporting of x-ray mammography in the first diagnosis of breast cancer: a Delphi consensus proposal. in La Radiologia medica / Radiol Med. 2022 May;127(5):471-483. doi: 10.1007/s11547-022-01478-5. Epub 2022 Mar 18.

2022
AOU Città della Salute di Torino
ASL Asti

Zuiani C; Scaperrotta GP; Sansone M; Sardanelli F; Saguatti G; Pediconi F; Nori J; Martincich L; Marino MA; Marini C; Iacconi C; Girardi V; Petrillo A; Frigerio A; Fusco R; Faggioni L; Cossu E; Coppola F; Calabrese M; Caumo F; Brancato B; Bernardi D; Belli P; Montemezzi S; Granata V; Neri E; Ciaghi E; Montella M; Miele V; et alii...

A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2022 Mar;30(3):2455-2465. doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15.

2022
ASL Torino 4
AOU Città della Salute di Torino

Ferri C; Parisi A; Ficorella C; Cortellini A; Pensieri MV; Aimar G; Roberto M; Petrillo A; Zoratto F; Spinelli GP; Garajova I; Vitale P; Zanaletti N; De Tursi M; Di Pietro FR; Morelli C; Giampieri R; Depetris I; Keränen SR; Lombardi P; Zurlo IV; Dell'Aquila E; Gelsomino F; Ghidini M; Nigro O; Filippi R; Salvatore L; Porzio G; Fargnoli MC; et alii...

Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis. in Frontiers in oncology / Front Oncol. 2022 Aug 12;12:935826. doi: 10.3389/fonc.2022.935826. eCollection 2022.

2022
ASL Torino 4
AOU Città della Salute di Torino

Berardi R; Galassi B; Ferri C; Garrone O; Zoratto F; Ciardiello D; Pensieri MV; Tomao S; Depetris I; Di Pietro FR; Dell'Aquila E; Giordano G; Landriscina M; Vitale P; Zurlo IV; De Tursi M; Di Marino P; Daniele B; Satolli MA; Petrillo A; Strippoli A; Filippi R; Bensi M; Maratta MG; Salvatore L; Ghidini M; Felicetti C; Giampieri R; Mammarella A; et alii...

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. in Clinical colorectal cancer / Clin Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. Epub 2021 Jul 18.

2021
ASL Torino 4
AOU Città della Salute di Torino

D'Orazio C; Ficorella C; Petrillo A; Ierino D; Spinelli GP; Roberto M; Zoratto F; Ghidini M; Vitale P; Garajova I; Troiani T; Di Pietro FR; De Galitiis F; Zanaletti N; Tinari N; Morelli C; Giampieri R; De Tursi M; Aimar G; Depetris I; Lombardi P; Keränen SR; Claudia F; Leo S; Dell'Aquila E; Spallanzani A; Zurlo V; Gelsomino F; Nigro O; et alii...

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. in Frontiers in oncology / Front Oncol. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. eCollection 2021.

2021
ASL Torino 4
AOU Città della Salute di Torino

Porzio G; Ficorella C; Ferri C; D'Orazio C; Patruno L; Petrillo A; Aimar G; Zoratto F; Roberto M; Spinelli GP; Garajova I; Vitale P; Zanaletti N; Morelli C; Di Marino P; Di Pietro FR; Depetris I; Giampieri R; Roselló Keränen S; Fulgenzi C; Lombardi P; Zurlo IV; Gelsomino F; Nigro O; Ghidini M; Tortora G; Salvatore L; Filippi R; Venditti O; et alii...